Drug intelligence / Profile preview

OS47720

Development stage: Preclinical
Lead developer: OncoSynergy
Modality: Small Molecules
Administration: Intraperitoneal

Overview

OS47720 is a preclinical-stage small molecule inhibitor of Heat Shock Protein 90 (HSP90) being developed by OncoSynergy. HSP90 is a molecular chaperone involved in the folding and stabilization of various client proteins, including those associated with neurodegenerative processes. By inhibiting HSP90, OS47720 is intended to modulate protein homeostasis (proteostasis) and potentially reduce the accumulation of toxic protein aggregates, such as tau or amyloid-beta, which are central to the pathogenesis of Alzheimer's disease. The program is currently in the preclinical phase of development.

Targets

HSP90 (Heat shock protein 90 chaperone complex)

Beyond the preview

Go deeper on OS47720.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OS47720.

Explore the full profile